Healthcare -
Biotechnology - NASDAQ - US
$ 1.16
-10.2 %
$ 58.9 M
Market Cap
-0.49
P/E
1. INTRINSIC VALUE
Balance Sheet
Cabaletta Bio, Inc.
| Current Assets | 167 M |
| Cash & Short-Term Investments | 164 M |
| Receivables | 0 |
| Other Current Assets | 2.71 M |
| Non-Current Assets | 18.4 M |
| Long-Term Investments | 0 |
| PP&E | 16.1 M |
| Other Non-Current Assets | 2.29 M |
| Current Liabilities | 27.1 M |
| Accounts Payable | 4.92 M |
| Short-Term Debt | 9.98 M |
| Other Current Liabilities | 12.2 M |
| Non-Current Liabilities | 5.62 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 5.62 M |
EFFICIENCY
Earnings Waterfall
Cabaletta Bio, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 125 M |
| Operating Income | -125 M |
| Other Expenses | -9.28 M |
| Net Income | -116 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cabaletta Bio, Inc.
| Net Income | -116 M |
| Depreciation & Amortization | 1.71 M |
| Capital Expenditures | -2.21 M |
| Stock-Based Compensation | 19.5 M |
| Change in Working Capital | 1.61 M |
| Others | 5.46 M |
| Free Cash Flow | -90.4 M |
Wall Street Analysts Price Targets
Cabaletta Bio, Inc.
Wall Street analysts predict an average 1-year price target for CABA of $16.3 , with forecasts ranging from
a
low of
$3 to a high of $32 .
CABA Lowest Price Target
Wall Street Target
3 USD
158.62%
CABA Average Price Target
Wall Street Target
16.3 USD
1308.05%
CABA Highest Price Target
Wall Street Target
32 USD
2658.62%
4. DIVIDEND
ANALYSIS
CABA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Cabaletta Bio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 – – Clinical and translational data on rese-cel to be presented in three oral presentations at the EULAR 2025 Congress in June – – Operational runway into 1H26 with cash and cash equivalents of $164.0 million as of December 31, 2024 – PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “We are looking forward to meeting with the FDA to align on registrational trial designs in myositis, which affects approximately 70,000 patients in the U.S., by leveraging our emerging clinical data and our efficient development strategy.
globenewswire.com
- 1 month ago
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption Program (TAP) on its automated cell therapy manufacturing Cell Shuttle™ for resecabtagene autoleucel, (rese-cel, previously known as CABA-201). Rese-cel is the lead clinical candidate in development by Cabaletta Bio, a biotechnology company focused on developing and launching the first curative targeted cell therapies designed spec.
businesswire.com
- 2 months ago
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:50 a.m. ET in Boston, MA.
globenewswire.com
- 2 months ago
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off or tapering steroids as of the latest follow-up –
globenewswire.com
- 2 months ago
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off steroids as of the latest follow-up – – Safety profile continues to suggest favorable risk-benefit in the first 10 patients dosed ; 90% of patients experienced either no CRS or Grade 1 CRS (fever) and 90% of patients experienced no ICANS – – Deep B cell depletion observed in all patients after rese-cel infusion with a transitional naïve B cell phenotype upon repopulation; tissue-resident B cell elimination confirmed by a lymph node biopsy in a scleroderma patient – – 50 clinical sites in the U.S. and Europe actively recruiting with 26 patients enrolled across the RESET™ clinical development program as of February 13, 2025 – PHILADELPHIA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced new and updated clinical data from the first 10 patients dosed with resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) across the RESET clinical development program. These data were presented by Aimee Payne, M.D.
globenewswire.com
- 2 months ago
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that updated clinical data on resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) will be featured in presentations at the 2025 American Association for the Advancement of Science Annual Meeting, which is being held at the Hynes Convention Center in Boston, MA from February 13-15, 2025, and the 5th International Conference on Lymphocyte Engineering, which is being held at the Holiday Inn Munich – City Center in Munich, Germany from February 20-22, 2025. The presentations will include safety, translational data and clinical outcomes from the first 10 patients dosed with rese-cel across multiple ongoing clinical trials in the RESET™ clinical development program.
globenewswire.com
- 3 months ago
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim's SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY.
globenewswire.com
- 3 months ago
Cabaletta Bio: Finding Optimism In Dire Straits
Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches.
seekingalpha.com
- 4 months ago
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash
I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, the company's strong cash position and lack of recent selling point to a bullish outlook. Super-positive testing results announced in mid-November would trigger significant stock gains, with the possibility of oversized returns on investment similar to 2022-23.
seekingalpha.com
- 6 months ago
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, which is being held at the Walter E. Washington Convention Center in Washington, D.C. from November 14-19, 2024. The presentations will feature new and updated clinical data on CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, which is being evaluated in multiple ongoing clinical trials in the RESET™ clinical development program.
globenewswire.com
- 7 months ago
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in September:
globenewswire.com
- 8 months ago
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling –
globenewswire.com
- 9 months ago
8. Profile
Summary
Cabaletta Bio, Inc. CABA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 58.9 M
Dividend Yield
0.00%
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Contact
2929 Arch Street, Philadelphia, PA, 19104
https://www.cabalettabio.com
IPO
Date
Oct. 25, 2019
Employees
161
Officers
Dr. Steven A. Nichtberger M.D.
Co-Founder, Chairman, Chief Executive Officer & President
Dr. Qing Sarah Yuan Ph.D.
Chief Technology Officer
Dr. Gwendolyn K. Binder Ph.D.
President of Science & Technology
Dr. David J. Chang FACR, M.D., M.P.H.
Chief Medical Officer
Mr. Anup Marda M.B.A.
Chief Financial Officer
Ms. Heather Harte-Hall M.Sc.
Chief Compliance Officer
Dr. Samik Basu M.D.
Chief Scientific Officer
Dr. Aimee Payne M.D., Ph.D.
Co-Founder & Co-Chair of Scientific Advisory Board
Mr. Michael Gerard J.D.
General Counsel & Secretary
Dr. Michael C. Milone M.D., Ph.D.
Co-Founder & Co-Chair of Scientific Advisory Board